Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. develops and sells ophthalmic medical technology for customized vision after cataract surgery. Its RxSight Light Adjustable Lens system includes Light Adjustable Lens products, the Light Delivery Device and related accessories, enabling post-operative adjustment of an intraocular lens based on patient visual feedback.
RxSight news commonly covers financial results, sales guidance, Light Adjustable Lens unit demand, Light Delivery Device placements and installed-base growth. Company updates also address clinical evidence presented in cataract and refractive surgery forums, regulatory approvals in international markets, healthcare conference participation and executive finance leadership changes.
RxSight (NASDAQ: RXST) will present at the 25th Annual Needham Virtual Healthcare Conference. Management will participate in a fireside chat on April 16, 2026 at 8:00 a.m. PT. A live and archived webcast will be available on the company investor relations website.
RxSight (NASDAQ: RXST) reported 2025 results: full-year revenue of $134.5 million (down 4%), gross profit of $103.0 million (76.6% margin), and a net loss of $38.9 million (‑$0.95 per share).
LAL unit sales rose 12% to 109,615 units; LDD system sales fell 48% with 163 units. Cash and short-term investments totaled $228.1 million. 2026 guidance: revenue $120.0–$135.0 million, gross margin 70%–72%, operating expenses $150.0–$160.0 million.
RxSight (NASDAQ:RXST) will report fourth quarter and full year 2025 financial results after market close on February 25, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and take questions.
Dial-in numbers, conference code 3406720, a live listen-only webcast and an archived recording will be available on the company’s investor relations website.
RxSight (Nasdaq: RXST) reported preliminary unaudited results for Q4 and full-year 2025 and named a new CFO effective Jan 11, 2026. Preliminary Q4 2025 revenue is expected to be approximately $32.6M, driven by sales of 28,611 Light Adjustable Lenses (LAL, +10% vs Q3 2025) and 25 Light Delivery Devices (LDD), bringing the installed base to 1,134 LDDs as of Dec 31, 2025. Preliminary FY2025 revenue is expected to be approximately $134.5M (vs prior guidance $125–$130M), with total LAL sales of 109,615 (+12% vs 2024) and 163 LDDs sold in 2025. Cash and short-term investments are expected to be $228.1M. Audited 2025 results and 2026 guidance will be released with Q4 earnings in February. Mark Wilterding is appointed CFO effective Jan 11, 2026.
RxSight (NASDAQ:RXST) announced that its management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 3:45 p.m. PT / 6:45 p.m. ET.
Investors and interested parties can access a live and archived webcast of the presentation at https://investors.rxsight.com/. No financial results or guidance were included in the announcement.
RxSight (NASDAQ:RXST) announced that Shelley Thunen, its Chief Financial Officer, is transitioning from the CFO role and will remain with the company until the sooner of her successor's appointment or January 31, 2026. Ms. Thunen has agreed to support RxSight as a consultant after the transition.
The release highlights Ms. Thunen's nearly decade of service, her role in the company's 2021 IPO, and operational achievements under her finance leadership, including more than 1,100 light-adjustable intraocular devices (LDDs) in the field and over 250,000 procedures performed. The CEO and board expressed gratitude for her contributions.
RxSight (NASDAQ: RXST) will present at the Piper Sandler 37th Annual Healthcare Conference in New York City.
Management is scheduled to present on Wednesday, December 3, 2025 at 12:00 p.m. ET. A live and archived webcast will be available at the company's investor site.
RxSight (Nasdaq: RXST) reported third quarter 2025 results: Q3 revenue $30.3M (down 14% YoY) driven by 26,045 LAL lenses sold (+6% procedure volume) and 25 LDD devices sold (-69%). Gross margin was 80% (+844 bps YoY). The company narrowed full‑year 2025 revenue guidance to $125.0M–$130.0M, raised full‑year gross margin guidance to 76%–77%, and kept operating expense guidance at $145M–$155M (including stock‑based comp of $30M–$32M). Cash and short‑term investments totaled $227.5M as of September 30, 2025.
RxSight (Nasdaq: RXST) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025.
Management will discuss results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. To join by phone dial (800) 715-9871 or (646) 307-1963 and enter conference code 6619966.
The call will be broadcast in listen-only mode and archived on the company investor relations site at https://investors.rxsight.com/.
RxSight (Nasdaq: RXST) will host multiple Live Learning Sessions at AAO 2025 in Orlando, Oct 18–20, at Booth #2931. Sessions feature surgeons sharing real-world experience with the Light Adjustable Lens, focusing on clinical advantages and economic implications of adjustability.
Scheduled talks run Oct 18 (10:00 AM–3:00 PM) and Oct 19 (10:00 AM–1:00 PM) and cover topics such as ROI, career impact, premium lens adoption, patient-centered outcomes, and practical counseling for Light Adjustable Lens patients.